At the news
? NEUTRALIMPACT 2/10 8-K filed Aug 4, 2026 at 08:48 ET
Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, effective September 1, 2026, with Tom Cavanaugh appointed as her successor. This is a routine leadership transition at a mega-cap pharmaceutical company with a named internal replacement, carrying no material financial impact.
- Jennifer Taubert to retire as EVP, Worldwide Chairman, Innovative Medicine effective September 1, 2026.
- Tom Cavanaugh appointed as successor, effective September 1, 2026, and will join the Executive Committee.
- Taubert had a 21-year tenure at J&J; under her leadership, Innovative Medicine grew to more than $60 billion in annual revenue.
- Cavanaugh has nearly 30 years of biopharma experience, including 9 years at J&J and prior roles at Celgene.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access